[Chronic autoimmune urticaria: treatment with omalizumab].
We report the case of a child with diagnosis of chronic urticaria/angioedema and its evolution upon omalizumab treatment.


METHODS
Our patient is a 12-years-old female who suffered for 14 months severe chronic urticaria/angioedema. She had a poor response to the highest doses of combined therapy with 3 antihistamines, steroids and anti-leukotrienes and great impairment of her quality of life. An autologous serum skin test was positive until 1:100 dilutions, leading to the diagnosis of chronic autoimmune urticaria. Due to the lack of response to treatment, therapy with omalizumab was administered. A notable reduction in symptoms toward the third dose was observed. After 12 months of this treatment, the patient is asymptomatic and has a negative autologous serum test.


CONCLUSIONS
Omalizumab could be a therapeutic option for patients with autoimmune urticaria unresponsive to other treatments.
Máspero
Jorge F
JF
Alergia Infantil, Hospital Alemán.
Parisi
Claudio A
CA
De Gennaro
Mónica
M
Benhabib
Osvaldo
O
Lampert
Marta
M
D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001327:Autoimmune Diseases / Q000188:drug therapy*; D002648:Child; D002908:Chronic Disease; D005260:Female; D006801:Humans; D000069444:Omalizumab; D014581:Urticaria / Q000188:drug therapy* / Q000276:immunology*
D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab